Počet záznamov: 1
protilátky bišpecifické
SYS d018033 LBL 00000nz--a2200000o--4500 005 20250606214806.4 008 930604|||anznnbabn-----------|-a|a------ 040 $b slo $a DNLM $d BA006 065 $a D12.776.124.486.485.114.125 065 $a D12.776.124.790.651.114.134 065 $a D12.776.377.715.548.114.134 066 $a 01 $c 03 150 $a protilátky bišpecifické $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 450 $w v $a Bifunctional Antibodies $2 eng 450 $w v $a Bispecific Antibodies $2 eng 550 $7 sllk_us_auth*d000918 $Y Antibody Specificity $w b $a špecifickosť protilátková 550 $7 sllk_us_auth*d003602 $Y Cytotoxicity, Immunologic $w b $a cytotoxicita imunologická 550 $7 sllk_us_auth*d007155 $Y Immunologic Factors $w P $a faktory imunologické 550 $7 sllk_us_auth*d000922 $Y Immunotoxins $w p $a imunotoxíny 550 $7 sllk_us_auth*d016499 $Y Radioimmunotherapy $w p $a rádioimunoterapia 665 $a 94 $2 eng 665 $a Antibodies (1985-1993) $2 eng 665 $a specific Antibodies (1985-1993) $2 eng 680 9-
$i Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors. $2 eng 680 $a do not coordinate with ANTIBODY FORMATION for /biosynthesis $2 eng 750 -2
$a Antibodies, Bispecific $2 eng 980 $x M
Počet záznamov: 1